Gladstone Institutional Advisory LLC Buys 14,500 Shares of Veru Inc. (NASDAQ:VERU)

Gladstone Institutional Advisory LLC grew its stake in shares of Veru Inc. (NASDAQ:VERU) by 34.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 56,876 shares of the company’s stock after buying an additional 14,500 shares during the period. Gladstone Institutional Advisory LLC’s holdings in Veru were worth $44,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Perceptive Advisors LLC increased its position in shares of Veru by 26.5% during the second quarter. Perceptive Advisors LLC now owns 7,063,277 shares of the company’s stock valued at $5,942,000 after buying an additional 1,478,578 shares during the period. Ikarian Capital LLC bought a new stake in shares of Veru during the first quarter valued at about $663,000. Alpine Global Management LLC increased its position in shares of Veru by 21.0% during the first quarter. Alpine Global Management LLC now owns 710,000 shares of the company’s stock valued at $497,000 after buying an additional 122,999 shares during the period. PVG Asset Management Corp bought a new stake in shares of Veru during the second quarter valued at about $474,000. Finally, Bank of New York Mellon Corp increased its position in shares of Veru by 1,718.2% during the second quarter. Bank of New York Mellon Corp now owns 443,782 shares of the company’s stock valued at $373,000 after buying an additional 419,374 shares during the period. 47.16% of the stock is currently owned by institutional investors.

Veru Trading Up 1.0 %

VERU stock opened at $0.74 on Wednesday. The company’s 50 day moving average is $0.82 and its 200 day moving average is $0.96. The stock has a market cap of $108.50 million, a price-to-earnings ratio of -1.54 and a beta of -0.47. Veru Inc. has a 1-year low of $0.36 and a 1-year high of $1.92.

Veru (NASDAQ:VERU) last announced its earnings results on Thursday, August 8th. The company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01). The company had revenue of $3.95 million during the quarter, compared to analysts’ expectations of $3.50 million. Veru had a negative net margin of 376.38% and a negative return on equity of 115.99%. During the same period in the prior year, the business earned ($0.13) earnings per share. As a group, sell-side analysts forecast that Veru Inc. will post -0.3 EPS for the current fiscal year.

Veru Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.